The government confirmed that the patient administration of the clinical II trial of a domestically developed blood system drug has been completed. As in the case of Celltrion's antibody treatment, the application for Conditional Marketing Authorization (CMA) is imminent.

Kwon Jun-wook, the 2nd vice-president of the Central Disease Control Headquarters said at a briefing on the current status of COVID-19 in Korea on the 7th, "Phase II clinical trials have been conducted at 13 medical institutions in relation to the clinical trials of blood system drugs currently being developed in Korea. In the situation where the medication was completed to 64 patients.”

In this regard, a total of 6,55